Field Demonstration of a Membrane Process to Recover Heavy Hydrocarbons and to Remove Water from Natural Gas

The objective of this project is to design, construct and field demonstrate a membrane system to recover natural gas liquids (NGL) and remove water from raw natural gas. An extended field test to demonstrate system performance under real-world high-pressure conditions is being conducted to convince industry users of the efficiency and reliability of the process. The system was designed and fabricated by Membrane Technology and Research, Inc. (MTR) and installed and operated at BP Amoco's Pascagoula, MS plant. The Gas Research Institute is partially supporting the field demonstration and BP-Amoco helped install the unit and provides onsite operators and utilities. The gas processed by the membrane system meets pipeline specifications for dew point and BTU value and can be delivered without further treatment to the pipeline. Based on data from prior membrane module tests, the process is likely to be significantly less expensive than glycol dehydration followed by propane refrigeration, the principal competitive technology. During the course of this project, MTR has sold 13 commercial units related to the field test technology, and by the end of this demonstration project the process will be ready for broader commercialization. A route to commercialization has been developed during this project and involves collaboration with other companies already servicing the natural gas processing industry

Field Demonstration of a Membrane Process to Recover Heavy Hydrocarbons and to Remove Water From Natural Gas Annual Report

The objective of this project is to design, construct and field demonstrate a 3-MMscfd membrane system to recover natural gas liquids (NGL) and remove water from raw natural gas. An extended field test to demonstrate system performance under real-world conditions is required to convince industry users of the efficiency and reliability of the process. The system will be designed and fabricated by Membrane Technology and Research, Inc. (MTR) and then installed and operated at British Petroleum (BP)-Amoco's Pascagoula, MS plant. The Gas Research Institute will partially support the field demonstration and BP-Amoco will help install the unit and provide onsite operators and utilities. The gas processed by the membrane system will meet pipeline specifications for dewpoint and Btu value and can be delivered without further treatment to the pipeline. Based on data from prior membrane module tests, the process is likely to be significantly less expensive than glycol dehydration followed by propane refrigeration, the principal competitive technology. At the end of this demonstration project the process will be ready for commercialization. The route to commercialization will be developed during this project and may involve collaboration with other companies already servicing the natural gas processing industry

Fenoldopam use in a burn intensive care unit: a retrospective study

<p>Abstract</p> <p>Background</p> <p>Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our study was to describe our use of low-dose fenoldopam (0.03-0.09 μg/kg/min) infusion in critically ill burn patients with AKI.</p> <p>Methods</p> <p>We performed a retrospective analysis of consecutive patients admitted to our burn intensive care unit (BICU) with severe burns from November 2005 through September 2008 who received low-dose fenoldopam. Data obtained included systolic blood pressure, serum creatinine, vasoactive medication use, urine output, and intravenous fluid. Patients on concomitant continuous renal replacement therapy were excluded. Modified inotrope score and vasopressor dependency index were calculated. One-way analysis of variance with repeated measures, Wilcoxson signed rank, and chi-square tests were used. Differences were deemed significant at p < 0.05.</p> <p>Results</p> <p>Seventy-seven patients were treated with low-dose fenoldopam out of 758 BICU admissions (10%). Twenty (26%) were AKI network (AKIN) stage 1, 14 (18%) were AKIN stage 2, 42 (55%) were AKIN stage 3, and 1 (1%) was AKIN stage 0. Serum creatinine improved over the first 24 hours and continued to improve through 48 hours (<it>p </it>< 0.05). There was an increase in systolic blood pressure in the first 24 hours that was sustained through 48 hours after initiation of fenoldopam (<it>p </it>< 0.05). Urine output increased after initiation of fenoldopam without an increase in intravenous fluid requirement (<it>p </it>< 0.05; <it>p </it>= NS). Modified inotrope score and vasopressor dependency index both decreased over 48 hours (<it>p </it>< 0.0001; <it>p </it>= 0.0012).</p> <p>Conclusions</p> <p>These findings suggest that renal function was preserved and that urine output improved without a decrease in systolic blood pressure, increase in vasoactive medication use, or an increase in resuscitation requirement in patients treated with low-dose fenoldopam. A randomized controlled trial is required to establish the efficacy of low-dose fenoldopam in critically ill burn patients with AKI.</p

Real-time three-dimensional transthoracic echocardiography in daily practice: initial experience

<p>Abstract</p> <p>Aim of the work</p> <p>To evaluate the feasibility and possible additional value of transthoracic real-time three-dimensional echocardiography (RT3D-TTE) for the assessment of cardiac structures as compared to 2D-TTE.</p> <p>Methods</p> <p>320 patients (mean age 45 ± 8.4 years, 75% males) underwent 2D-TTE and RT3D-TTE using 3DQ-Q lab software for offline analysis. Volume quantification and functional assessment was performed in 90 patients for left ventricle and in 20 patients for right ventricle. Assessment of native (112 patients) and prosthetic (30 patients) valves morphology and functions was performed. RT3D-TTE was performed for evaluation of septal defects in 30 patients and intracardiac masses in 52 patients.</p> <p>Results</p> <p>RT3D-TTE assessment of left ventricle was feasible and reproducible in 86% of patients while for right ventricle, it was (55%). RT3D-TTE could define the surface anatomy of mitral valve optimally (100%), while for aortic and tricuspid was (88% and 81% respectively). Valve area could be planimetered in 100% for the mitral and in 80% for the aortic. RT3D-TTE provided a comprehensive anatomical and functional evaluation of prosthetic valves. RT3D-TTE enface visualization of septal defects allowed optimal assessment of shape, size, area and number of defects and evaluated the outcome post device closure. RT3D-TTE allowed looking inside the intracardiac masses through multiple sectioning, valuable anatomical delineation and volume calculation.</p> <p>Conclusion</p> <p>Our initial experience showed that the use of RT3D-TTE in the assessment of cardiac patients is feasible and allowed detailed anatomical and functional assessment of many cardiac disorders.</p

Potential dopamine-1 receptor stimulation in hypertension management.

The role of dopamine receptors in blood pressure regulation is well established. Genetic ablation of both dopamine D1-like receptor subtypes (D1, D5) and D2-like receptor subtypes (D2, D3, D4) results in a hypertensive phenotype in mice. This review focuses on the dopamine D1-like receptor subtypes D1 and D5 (especially D1 receptors), as they play a major role in regulating sodium homeostasis and blood pressure. Studies mostly describing the role of renal dopamine D1-like receptors are included, as the kidneys play a pivotal role in the maintenance of sodium homeostasis and the long-term regulation of blood pressure. We also attempt to describe the interaction between D1-like receptors and other proteins, especially angiotensin II type 1 and type 2 receptors, which are involved in the maintenance of sodium homeostasis and blood pressure. Finally, we discuss a new concept of renal D1 receptor regulation in hypertension that involves oxidative stress mechanisms

FIELD DEMONSTRATION OF A MEMBRANE PROCESS TO RECOVER HEAVY HYDROCARBONS AND TO REMOVE WATER FROM NATURAL GAS

The objective of this project is to design, construct and field demonstrate a 3-MMscfd membrane system to recover natural gas liquids (NGL) and remove water from raw natural gas. An extended field test to demonstrate system performance under real-world conditions is required to convince industry users of the efficiency and reliability of the process. The system will be designed and fabricated by Membrane Technology and Research, Inc. (MTR) and then installed and operated at British Petroleum (BP)-Amoco's Pascagoula, MS plant. The Gas Research Institute will partially support the field demonstration and BP-Amoco will help install the unit and provide onsite operators and utilities. The gas processed by the membrane system will meet pipeline specifications for dewpoint and Btu value and can be delivered without further treatment to the pipeline. Based on data from prior membrane module tests, the process is likely to be significantly less expensive than glycol dehydration followed by propane refrigeration, the principal competitive technology. At the end of this demonstration project the process will be ready for commercialization. The route to commercialization will be developed during this project and may involve collaboration with other companies already servicing the natural gas processing industry. Document type: Repor